Stellantis Q2 Vehicle Shipments Rise 10% as North America Drives Growth 
Rio Tinto Reports Strong Q2 Iron Ore Sales, Maintains 2026 Production Outlook 
Yaskawa Electric Shares Slide as Weak Profit Overshadows Strong AI Demand 
Richemont Q1 Sales Beat Forecast as Cartier Demand Drives Strong Growth 
Apple Intelligence Cleared for China as Alibaba and Baidu AI Power iPhone Features 
Australia Flags Child Safety Gaps at Apple, Meta, Google Over Online Sexual Extortion 
DBS Targets S$1 Trillion Wealth AUM by 2030 Amid Asia Wealth Boom 
Mastercard Explores Sale of Majority Stake in UK Payments Firm Vocalink: Report 
Volkswagen Launches €28,000 ID. Cross EV as Europe’s Electric Vehicle Demand Accelerates 
Taiwan Mangoes Head to Europe as Premium Fruit Exports Expand 
SK Hynix Stock Soars as AI Memory Demand Outlook Fuels Chip Rally 
Arm Stock Falls After HSBC Downgrade, Citing Limited Near-Term AI Upside 
SK Hynix Shares Drop After Strong Nasdaq Debut Despite $26 Billion ADR Listing 
BHP Faces Major Port Hedland Strike as Labor Talks Stall Ahead of Production Report 
Genesis Minerals to Acquire Vault in A$5.6 Billion Deal After Regis Withdraws 
Muji Owner Ryohin Keikaku Stock Soars After Raising Full-Year Earnings Forecast 
Nippon Paint Reportedly Offers Up to €7.5 Billion for Akzo Nobel Decorative Paints Business 
NEW YORK, Jan. 14, 2016 (GLOBE NEWSWIRE) -- Microlin Bio, Inc., a development stage biotechnology company focused on the development of microRNA based therapeutics for cancer, today announced the change of its trading symbol from AMIB to MICB. The change will take effect on January 14, 2016.
The new trading symbol, which is more closely aligned with the Company’s name, is intended to strengthen the Microlin Bio brand and increase its profile within the investment community.
Beginning January 14, 2016 all information, including stock trading, SEC filings, and market data related to Microlin Bio, will be reported under the new ticker symbol, “MICB.” The CUSIP for company’s common stock will remain unchanged. Outstanding stock certificates are not affected by the symbol change and will not need to be exchanged.
About microRNA
MicroRNAs are recently discovered naturally occurring RNA molecules (composed of 19 to 25 nucleotides) that do not encode proteins but instead regulate gene expression and various biological pathways. The improper balance of microRNAs are linked to many diseases, including cancer. As such, replacement or inhibition of deregulated microRNAs may act as a potent means to treat cancers.
About Microlin Bio, Inc.
Microlin Bio, Inc. is a development stage biotechnology company focused primarily on the development of microRNA based therapeutics to treat cancer from technologies licensed from Ohio State University. This includes over 138 pending patent applications and 132 granted patents covering numerous microRNAs. For more information, please visit www.microlinbio.com.
Microlin Bio Forward-Looking Statements
This press release contains “forward-looking statements” as that term is defined in the Private Securities Litigation Reform Act of 1995, regarding the research, development and commercialization of pharmaceutical products. Such forward-looking statements are based on current expectations and involve inherent risks and uncertainties, including factors that could delay, divert or change any of them, and could cause actual outcomes and results to differ materially from current expectations. No forward-looking statement can be guaranteed. Forward-looking statements in the press release should be evaluated together with the many uncertainties that affect Microlin Bio’s business and Microlin Bio undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.
The Ruth Group Lee Roth (investors) [email protected] (646) 536-7012 Ashley Brown (media) [email protected] (646)536-7002
